Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between -140 million and -170 million yuan, indicating a loss compared to the same period last year [1][2] - The expected net profit after deducting non-recurring gains and losses for the first half of 2025 is also projected to be between -140 million and -170 million yuan [1][2] Group 2 - The main reasons for the anticipated loss include a decline in sales prices of key products like urea due to macroeconomic conditions and government policies affecting the fertilizer industry, as well as a significant decrease in export volumes [2] - The report period saw a continuous rise in international sulfur prices, leading to increased procurement costs for domestic sulfur and sulfuric acid, as well as a notable rise in potassium fertilizer prices, which contributed to higher costs for phosphate fertilizer products [2] - There was an increase in the provision for various impairment losses compared to the previous year [2]

[Anhui Liuguo Chemical Co., Ltd. 2025 Semi-Annual Performance Pre-Loss Announcement](index=1&type=section&id=Anhui%20Liuguo%20Chemical%20Co.%2C%20Ltd.%202025%20Semi-Annual%20Performance%20Pre-Loss%20Announcement) [Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts an unaudited net loss for H1 2025, with attributable net profit between -RMB 140 million and -RMB 170 million, reversing prior year's profit 2025 H1 Estimated Performance | Performance Indicator | 2025 H1 Estimate | | :--- | :--- | | Net Profit Attributable to Parent Company Owners | -RMB 140 million to -RMB 170 million | | Net Profit Attributable to Parent Company Owners (Excluding Non-recurring Items) | -RMB 140 million to -RMB 170 million | - These performance forecast figures are **unaudited** by a certified public accountant[4](index=4&type=chunk) [Prior Period Performance Comparison](index=1&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Condition) In H1 2024, the company achieved profitability, reporting attributable net profit of RMB 29.37 million and EPS of RMB 0.06, contrasting the current period's forecast loss 2024 H1 Performance | Performance Indicator | 2024 H1 | | :--- | :--- | | Net Profit Attributable to Parent Company Owners | RMB 29.37 million | | Net Profit Attributable to Parent Company Owners (Excluding Non-recurring Items) | RMB 10.08 million | | Earnings Per Share | RMB 0.06 | [Analysis of Performance Pre-Loss Reasons](index=2&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Pre-Loss) The company's projected loss is attributed to declining product prices and export volumes, rising raw material costs for phosphorus fertilizers, and increased impairment provisions - Revenue pressure stems from declining sales prices and significantly reduced export volumes for key products like urea, influenced by macroeconomic conditions and national price stabilization and export control policies[7](index=7&type=chunk) - Cost increases are driven by a substantial year-over-year rise in international sulfur prices, impacting domestic sulfur and sulfuric acid procurement, alongside significant increases in potash fertilizer purchase prices, collectively elevating phosphorus fertilizer production costs[7](index=7&type=chunk) - Increased impairment provisions during the reporting period have further impacted current period profit[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) This performance forecast is a preliminary, unaudited estimate based on current operations, with no material uncertainties affecting its accuracy - This performance forecast represents the company's preliminary estimate based on operating conditions and has not been audited by an accounting firm[8](index=8&type=chunk) [Other Explanations](index=2&type=section&id=V.%20Other%20Explanations) The company advises investors that disclosed figures are preliminary; final accurate financial data will be based on the official 2025 semi-annual report, urging caution regarding investment risks - The final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to exercise caution regarding investment risks[9](index=9&type=chunk)

六国化工（600470）公告，预计2025年半年度实现归属于母公司所有者的净利润为-1.4亿元到-1.7亿 元，与上年同期相比出现亏损。预计2025年半年度实现归属于母公司所有者的扣除非经常性损益后的净 利润为-1.4亿元到-1.7亿元。报告期内，受宏观经济环境和国家对化肥行业稳价保供、出口管控等政策 的影响，公司主要产品尿素等销售价格同比下跌，产品出口销量同比有较大幅度下降。同时，国际硫磺 价格持续攀升，国内硫磺、硫酸采购价格同比大幅上涨，钾肥采购价同比也有较大幅度上涨，导致公司 磷肥产品成本同比上升。 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

股票简称：六国化工 股票代码：600470 公告编号：2025-041 安徽六国化工股份有限公司董事会 2025年7月2日 梁晨先生任职期间恪尽职守，勤勉尽责，公司董事会对梁晨先生任职期间 为公司发展做出的贡献表示衷心感谢！ 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 安徽六国化工股份有限公司（以下简称"公司"）董事会近日收到副总经 理梁晨先生的书面辞职报告，梁晨先生因工作变动，辞去公司副总经理职务。 根据《公司法》和《公司章程》的有关规定，梁晨先生的辞职报告自送达公司 董事会时生效。辞职后，不再担任公司及子公司任何职务，截至本公告披露 日，梁晨先生未持有公司股票。 ...

Group 1 - The chemical sector experienced a significant rebound, driven by the strength in oil and gas stocks, leading to widespread gains across the industry [1] - Xinghua Co. achieved a limit-up increase, marking its third consecutive day of gains over a seven-day period [1] - Other companies such as Six National Chemical, Zhongyida, Danhua Technology, and Bohai Chemical also reached their daily limit-up, indicating strong market performance [1]

Core Viewpoint - The legal opinion from Tianhe Law Firm confirms that the 2025 Second Extraordinary General Meeting of Anhui Liuguo Chemical Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][10]. Group 1: Meeting Procedures - The meeting was announced on May 30, 2025, through various media outlets, including Shanghai Securities News and the Shanghai Stock Exchange website [1]. - The meeting took place on June 18, 2025, at 14:30 in the company's first conference room, chaired by the company's chairman, Mr. Chen Shengqian [2]. - The network voting was available from 9:15 to 15:00 on the same day, with specific time slots for voting through the Shanghai Stock Exchange system [2]. Group 2: Attendance and Voting - A total of 361 participants attended the meeting, representing 137,327,771 shares, which is 26.3281% of the company's total shares [2][3]. - The attendees included shareholders, their proxies, some directors, supervisors, senior management, and Tianhe lawyers, all of whom met the legal qualifications to participate [3]. Group 3: Voting Procedures and Results - The voting was conducted through a named voting method, with results compiled from both on-site and online votes [4]. - The voting results showed a high level of agreement on the proposed resolutions, with the first resolution receiving 136,337,871 votes in favor, accounting for 99.2791% of the votes cast [4][5]. - Subsequent resolutions also received similar levels of support, with votes in favor ranging from 99.3243% to 99.3588% [5][6][7]. Group 4: Legal Validity - Tianhe Law Firm concluded that all aspects of the meeting, including the convening, attendance, and voting procedures, complied with the Company Law, the rules of the shareholders' meeting, and the company's articles of association, affirming the legality and validity of the resolutions passed [10].

Core Viewpoint - The announcement details the resolutions passed during the first meeting of the ninth board of directors of Anhui Liuguo Chemical Co., Ltd, including the election of new board members and the appointment of key executives [1][2][3]. Group 1: Board Elections and Appointments - The ninth board of directors was elected during the second extraordinary general meeting of 2025, with all candidates approved [1]. - Wu Ya was elected as the chairman of the ninth board of directors, with unanimous support (9 votes in favor) for a term of three years [1][2]. - Ma Jian was appointed as the executive director and legal representative of the company, also receiving unanimous support (9 votes in favor) [2]. Group 2: Executive Appointments - The board approved the appointment of Ma Jian as the general manager for a term of three years, with unanimous support (9 votes in favor) [2][3]. - Three vice general managers were appointed: Yu Yun, Liang Chen, and Xu Zheng, all for a term of three years, with unanimous support (9 votes in favor) [2][3]. - The board appointed Xing Jin'e as the secretary of the board, Wang Xianlong as the financial director, and Zhou Ying as the securities affairs representative, all receiving unanimous support (9 votes in favor) [3][4][5][6][7][8]. Group 3: Committee Adjustments - The board made adjustments to the four specialized committees in accordance with relevant regulations, ensuring compliance with the Company Law and corporate governance standards [2][4].

Group 1 - The company held its second extraordinary general meeting of shareholders on June 18, 2025, to elect the ninth board of directors and subsequently convened the first meeting of the new board [1][2] - The ninth board of directors consists of 9 members, including 3 independent directors and 1 employee director, with a term of three years starting from the approval date of the extraordinary general meeting [2] - The board has established four specialized committees: Strategy Committee, Nomination Committee, Audit Committee, and Compensation and Assessment Committee [1][2] Group 2 - The members of the ninth board of directors include non-independent directors Wu Ya (Chairman), Pan Ming, Wang Gang, Ma Jian, Li Hailong, and Zhao Hui (employee director), along with independent directors Zhang Chen, Lu Manman, and Li Pengfeng [2] - The board has appointed six senior management personnel and one securities affairs representative, with Ma Jian as the General Manager and Wang Xianlong as the Chief Financial Officer [2] - The company expressed gratitude to the eighth board of directors and the supervisory board for their diligence and contributions during their tenure [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 安徽六国化工股份有限公司（以下简称"公司"）于2025年6月18日召 开了2025年第二次临时股东代表大会，选举产生了公司第九届董事会非职工 代表董事；近日召开了五届五次职工代表大会团组长联席会议，选举产 生了公司第九届董事会职工代表董事；于2025年6月18日在公司第一会议室 召开了第九届董事会第一次会议，会议分别审议通过了选举董事长、选举董 事会专门委员会委员、聘任总经理、副总经理等相关议案。公司董事会已完 成换届，现将公司董事会换届选举及聘任高级管理人员、证券事务代表的具 体情况公告如下： 一、公司第九届董事会组成情况 股票简称：六国化工 股票代码：600470 公告编号：2025-040 根据公司2025年第二次临时股东大会及第九届董事会第一次会议选举结 果，公司第九届董事会共有9名董事组成，其中独立董事3名，职工董事1名。 公司第九届董事会下设战略委员会、提名委员会、审计委员会、薪酬与考核 委员会4个专门委员会。 （一）公司第九届董事会成员 非独立董事：吴亚先生（董事长 ...